Braidwell »

Vir Biotechnology shares owned by Braidwell

Quarter-by-quarter ownership of Vir Biotechnology (VIR) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Vir Biotechnology

Tip: Access up to 7 years of quarterly data

All positions including Vir Biotechnology held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vir Biotechnology by Braidwell

Quarter filed Position value Share count Share price at filing
2023-06-30 $18M 729k 24.53
2023-03-31 $14M 604k 23.27

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Vir Biotechnology

Vanguard Group
Baillie Gifford & Co
Citadel Advisors
Alliancebernstein
Bill & Melinda Gates Foundation
D. E. Shaw & Co
Charles Schwab Investment Management
Bank of New York Mellon
Goldman Sachs Group
Voloridge Investment Management
UBS Group
Principal Financial Group
Dimensional Fund Advisors
Barclays
Millennium Management

View all funds holding Vir Biotechnology